CPT code 87183 designates a laboratory molecular diagnostic procedure that detects carbapenem resistance genes in organisms grown from patient specimens using an amplified probe technique. This testing identifies specific resistance determinants such as blaKPC, blaNDM, blaVIM, blaOXA-48, and blaIMP and is reported per isolate. The code is important nationally because detection of carbapenemase genes informs infection control, antimicrobial stewardship, and public health surveillance efforts tied to multidrug-resistant gram-negative infections.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find clinical context about the test’s role in identifying carbapenem resistance, expected service setting (clinical or hospital laboratory), and operational considerations tied to reporting per isolate. The publication also summarizes benchmarks and policy-relevant topics such as reimbursement considerations across major payers, coding guidance for laboratory reporting, and intersections with antimicrobial resistance monitoring. Where specific payer policies or code pairings are not provided in the input, the text notes that those data are not available in the input.